Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | ELANE | P08246 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
| ▸ | ACR | P10323 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27498354 | 1.00 | LMNA (0.55) | LMNAELANEALDH1A1PRSS1ACR | |
| SCHEMBL15679080 | 0.92 | ELANE (0.55) | LMNAELANEALDH1A1MAPTKMT2A | |
| SCHEMBL23493150 | 0.92 | ELANE (0.55) | LMNAELANEALDH1A1MAPTKMT2A | |
| Hydrochloric Acid SCHEMBL30184762 | 0.90 | ELANE (0.53) | LMNAELANEALDH1A1MAPTKMT2A | |
| SCHEMBL18295352 | 0.85 | LMNA (0.52) | LMNAELANEALDH1A1PRSS1ACR | |
| SCHEMBL26824432 | 0.85 | LMNA (0.52) | LMNAELANEALDH1A1PRSS1ACR | |
| SCHEMBL3199570 | 0.84 | ELANE (0.48) | LMNAELANEALDH1A1GAACYP1A2 | |
| SCHEMBL15679089 | 0.84 | ELANE (0.48) | ELANEGAAMAPTKMT2AMEN1 | |
| SCHEMBL28291161 | 0.84 | ELANE (0.48) | LMNAELANEALDH1A1GAACYP1A2 | |
| SCHEMBL2402636 | 0.84 | ELANE (0.48) | ELANEGAAMAPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105636975-A | Anti-inflammatory tripeptides | DR AUGUST WOLFF GMBH & CO KG ARZNEIMITTEL | 2016-06-01 | — | — | CN | claimed |
| CN-113396218-B | Engineered transaminase polypeptides | 科德克希思公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-118812647-A | Novel insect short neuropeptide sNPF analogue and application thereof | 四川轻化工大学 | 2024-10-22 | — | — | CN | disclosed |
| EP-4136102-A1 | LONG ACTING PEPTIDE TYROSINE TYROSINE (PYY) ANALOGS AND METHODS OF USE | I2O Therapeutics, Inc. (US) | 2023-02-22 | — | — | EP | disclosed |
| WO-2021212023-A1 | LONG ACTING PEPTIDE TYROSINE TYROSINE (PYY) ANALOGS AND METHODS OF USE | INTARCIA THERAPEUTICS, INC. (US) | 2021-10-21 | — | — | WO | disclosed |
| CN-110520147-A | For treating the composition and method of iron overload | LA JOLLA PHARMA CO | 2019-11-29 | — | — | CN | disclosed |
| CN-110392685-A | Selective sulfonation of benzodiazepine derivatives | 伊缪诺金公司 | 2019-10-29 | — | — | CN | disclosed |
| CN-110312521-A | Method of administering hepcidin | 拉卓拉药物公司 | 2019-10-08 | — | — | CN | disclosed |
| CN-110267971-A | Immunomodulator | 百时美施贵宝公司 | 2019-09-20 | — | — | CN | disclosed |
| CN-105636975-B | Anti-inflammatory tripeptides | 奥古斯特沃尔夫博士有限两合公司-医药 | 2019-06-25 | — | — | CN | disclosed |
| CN-1582149-A | Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels | PROBIODRUG AG (DE) | 2005-02-16 | — | — | CN | disclosed |
| CN-1460023-A | Polymer modified bioactive synthetic chemokines and methods of production and use | GRYPHON TREAT CO (US) | 2003-12-03 | — | — | CN | disclosed |
| US-20030114362-A1 | Penta-or tetrapeptide binding to somatostatin receptors and the use of the same | NOVASPIN BIOTECH GMBH (DE) | 2003-06-19 | — | — | US | disclosed |
| CN-1407856-A | Method of improving dough and bread quality | DANISCO (DK) | 2003-04-02 | — | — | CN | disclosed |
| WO-2002100885-A2 | A PENTA- OR TETRAPEPTIDE BINDING TO SOMATOSTATIN RECEPTORS AND THE USE OF THE SAME | NOVASPIN BIOTECH GMBH (DE) | 2002-12-19 | — | — | WO | disclosed |
| EP-0721468-B1 | PLATELET AGGREGATION INHIBITORY PEPTIDES | NIPPON STEEL CORP (JP) | 2001-05-30 | — | — | EP | disclosed |
| US-5721213-A | Peptides, active as inhibitors of platelet aggregation | NIPPON STEEL CORPORATION (JP) | 1998-02-24 | — | — | US | disclosed |
| EP-0721468-A1 | NOVEL PEPTIDE, ACTIVE AS INHIBITORS OF PLATELET AGGREGATION | NIPPON STEEL CORPORATION (JP) | 1996-07-17 | — | — | EP | disclosed |
| WO-1995009185-A1 | NOVEL PEPTIDE, ACTIVE AS INHIBITORS OF PLATELET AGGREGATION | NIPPON STEEL CORPORATION (JP) | 1995-04-06 | — | — | WO | disclosed |
| EP-0331404-A2 | Method for producing tropane alkaloid | SEITAIKINOU RIYOU KAGAKUHIN SHINSEIZOUGIJUTSU KENKYU KUMIAI (JP) | 1989-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114362-A1 | Penta-or tetrapeptide binding to somatostatin receptors and the use of the same | SSTR5, SSTR3, SCTR | LMNA 2982/4885ELANE 302/4885ALDH1A1 4540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.